Topic
Weight Loss
GLP-1 muscle loss and the drugs built to preserve lean mass during weight loss — Ozempic, bimagrumab, trevogrumab, and the obesity pipeline.
5 articles
Activin E (INHBE): The Liver Hormone Behind the Next Obesity Drugs
Activin E is the liver-made cousin of myostatin and activin A. People born with low activin E carry less belly fat and get diabetes less often, and three biotechs are now silencing it to copy that effect.
Taldefgrobep Alfa: Biohaven's Bet on Muscle-Preserving Weight Loss
Taldefgrobep alfa missed its SMA primary endpoint, but its body-composition data was strong enough to relaunch Biohaven as a contender in the muscle-sparing obesity race. Here is the full status as of May 2026.
Myostatin Inhibitors and Obesity: The New Class of Weight-Loss Drugs
Myostatin inhibitors became the new obesity story because GLP-1 drugs strip too much muscle. Here is the full 2026 pipeline: bimagrumab, apitegromab, trevogrumab, taldefgrobep, and the realistic limits.
Myostatin Inhibitors and GLP-1 Muscle Loss: What Ozempic Users Should Know
GLP-1 drugs strip muscle along with fat. This guide breaks down the real numbers, the bimagrumab plus semaglutide data, the trevogrumab COURAGE trial, taldefgrobep, and what is actually buyable in 2026.
Bimagrumab: The Activin Receptor Antibody Lilly Paired With Semaglutide
Bimagrumab is the ActRII antibody Lilly bought for 1.9 billion dollars. Here is the BELIEVE trial data, the JAMA T2DM results, the muscle-spasm problem, and why Lilly hit pause.